Format

Send to

Choose Destination
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12.

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.

Author information

1
Center of Internal Medicine, Goethe University, Frankfurt, Germany.
2
Amgen Research (Munich) GmbH, Germany gerhardz@amgen.com.
3
Amgen Research (Munich) GmbH, Germany.
4
Medical Department A, University of Münster, Germany.
5
Department for Internal Medicine III, University Ulm, Germany.
6
Medical Department II, Christian-Albrechts University, Kiel, Germany.
7
Department of Haematology, Cardiff University, Cardiff, UK.
8
Department for Hematology and Oncology and Tumor Immunology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
9
Metronomia Clinical Research GmbH, München, Germany.
10
Department of Internal Medicine II, Universitätsklinikum, Würzburg, Germany.
11
Comprehensive Cancer Center Mainfranken, Universitätsklinikum Würzburg, Germany.
PMID:
28082340
PMCID:
PMC5395124
DOI:
10.3324/haematol.2016.153957
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center